Generic Semaglutide vs Ozempic

Novo Nordisk's data exclusivity on semaglutide in Canada expired on January 4, 2026, opening the door for other manufacturers to file for approval of their own versions of the same active molecule. Apotex was among the first out of the gate, launching Apo-Semaglutide in May 2026, with Dr. Reddy's following shortly after with its own version. At Costco, Apo-Semaglutide has been pricing from around $88 a month — a fraction of Ozempic's retail list price. More generic manufacturers, including Sandoz and Teva, are reported to have applications under review, and the general expectation among pharmacists tracking this category is that prices will keep drifting down through the rest of 2026 as competition increases.

It's worth being precise about what 'generic' means here: these are Health Canada-approved products that reference the same active ingredient and have gone through the standard generic-approval bioequivalence process. That's a materially different category from compounded or grey-market semaglutide products sold outside the regulated pharmacy supply chain, which are not equivalent, are not covered here, and carry risks a regulated generic doesn't.

Novo Nordisk didn't sit still once exclusivity lapsed. The company launched its own authorized generic, sold under the name Plosbrio, which is chemically the same product as Ozempic sold without the brand's marketing and pricing structure. That's one lever Novo pulled. The second, and the one that changes this comparison the most, is the savings card available through ozempic.ca.

That savings program can bring the effective price a patient pays for brand-name Ozempic down close to what a generic costs at retail, and critically, it doesn't require advance registration or a lengthy approval process for many eligible patients — it's applied at the pharmacy counter. This is the wrinkle that makes a simple list-price comparison misleading: on paper, $88 versus $250-plus looks like a wide gap, but for a patient who qualifies for the savings card, the real out-of-pocket difference between brand Ozempic and the cheapest generic can shrink dramatically, sometimes down to a matter of dollars a month rather than over a hundred.

The upshot is that neither the generic's list price nor Ozempic's list price fully describes what any individual patient will actually pay. A patient without private insurance and without the savings card genuinely benefits from choosing the generic if their pharmacy stocks it and their prescriber is comfortable with the substitution. A patient who does qualify for Novo's savings program may find that the brand-name product, after the discount, costs roughly the same as the generic — in which case the decision comes down to pharmacy stock, prescriber preference, and pen-device familiarity rather than price.

There's also an availability dimension that a price table can't capture: generic semaglutide launched in May 2026 and stock is still building across the country, so not every pharmacy carries it yet, while Ozempic remains close to universally available. A patient choosing on price alone should confirm their local pharmacy actually has the generic in stock before assuming the lower number applies to them.